Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities-Reference-Cited by-同舟云学术

Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities

Published:2022-06-28 Issue:7 Volume:1 Page:
ISSN:2766-5526
Container-title:NEJM Evidence
language:en
Short-container-title:NEJM Evidence

Author:

Kater Arnon P.¹,Owen Carolyn²,Moreno Carol³,Follows George⁴,Munir Talha⁵,Levin Mark-David⁶,Benjamini Ohad⁷,Janssens Ann⁸,Osterborg Anders⁹,Robak Tadeusz¹⁰,Simkovic Martin¹¹,Stevens Don¹²,Voloshin Sergey¹³,Vorobyev Vladimir¹⁴,Ysebaert Loic¹⁵,Qin Rui¹⁶,Steele Andrew J.¹⁷,Schuier Natasha¹⁸,Baeten Kurt¹⁹,Caces Donne Bennett¹⁶,Niemann Carsten U.²⁰

Affiliation:

1. Amsterdam University Medical Centers, Cancer Center Amsterdam, University of Amsterdam, on behalf of the HOVON CLL Working Group, Amsterdam

2. Tom Baker Cancer Centre, Calgary, Alberta, Canada

3. Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona

4. Addenbrooke’s Hospital, Cambridge, UK

5. St James’s Hospital, Leeds, UK

6. Albert Schweitzer Hospital, Dordrecht, Netherlands

7. Sheba Medical Center, Ramat Gan, Israel

8. Universitaire Ziekenhuizen Leuven, Leuven, Belgium

9. Karolinska University Hospital, Stockholm

10. Medical University of Łódź, Copernicus Memorial Hospital, Łódź, Poland

11. University Hospital Hradec Králové, Hradec Králové, Czech Republic

12. Norton Cancer Institute, Louisville, KY

13. Russian Scientific Research Institute of Hematology and Transfusiology, St. Petersburg, Russia

14. S.P. Botkin Moscow City Clinical Hospital, Moscow

15. Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France

16. Janssen Research & Development, Raritan, NJ

17. Janssen Research & Development, San Diego, CA

18. Janssen Research & Development, Düsseldorf, Germany

19. Janssen Research & Development, Beerse, Belgium

20. Rigshospitalet Copenhagen University Hospital, Copenhagen

Publisher

Massachusetts Medical Society

Reference43 articles.

1. National Cancer Institute Surveillance Research Program. SEER*Explorer: An interactive website for SEER cancer statistics. 2021 (https://seer.cancer.gov/explorer/).

2. Updates in the management of chronic lymphocytic leukemia/small lymphocytic leukemia

3. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

4. Management of Chronic Lymphocytic Leukemia in the Elderly

5. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial;Gastric Cancer;2024-02-03

2. Conditional survival to assess prognosis in patients with chronic lymphocytic leukemia;Annals of Hematology;2024-02-03

3. The GLOW trial in chronic lymphocytic leukaemia;The Lancet Oncology;2024-02

4. Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease;New England Journal of Medicine;2024-01-25

5. Identifying CLL patients at high risk of atrial fibrillation on treatment using machine learning;Leukemia & Lymphoma;2024-01-05